Photo by nci from unsplash
e15535Background: The C-TASK FORCE trial demonstrated that TAS-102 plus bevacizumab might become a potential treatment option for patients with metastatic colorectal cancer (mCRC) in a refractory s... Click to show full abstract
e15535Background: The C-TASK FORCE trial demonstrated that TAS-102 plus bevacizumab might become a potential treatment option for patients with metastatic colorectal cancer (mCRC) in a refractory s...
Keywords:
102 plus;
metastatic colorectal;
colorectal cancer;
tas 102;
plus bevacizumab
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!